Navigation Links
New Study Identifies Better Solution for Itch

SAN DIEGO, April 3, 2013 /PRNewswire/ -- Shoppers spend more than $352 million annually on anti-itch remedies and they are faced with a wealth of options of over-the-counter products on store shelves.  A new study published in the international peer-reviewed journal, Acta Dermato-Venereologica, may just help itch sufferers zero in on the most effective remedies.


Researchers at the Wake Forest School of Medicine compared a topical hydrogel containing aluminum acetate and strontium (sold commercially as TriCalm Hydrogel) head-to-head against two products commonly marketed for anti-itch; hydrocortisone and diphenhydramine (Benadryl 1%).  TriCalm was "significantly superior" to the other two over-the-counter anti-itch agents reducing both the peak intensity and duration of the subjects' itch, according to the results of the study.

"Managing itch, especially chronic itch, is challenging," said Gil Yosipovitch, MD, of the Dermatology Department at Wake Forest University and one of the study's authors. "Many of the typical over-the-counter remedies are not effective and what this study tells us is that TriCalm products are likely a more effective solution than other over-the-counter options."

The double blinded, vehicle-controlled study was looking specifically at non-histamine induced itches.  The researchers induced itch in the subjects using a tropical plant called cowhage typically used when studying non-histamine-induced itch, This type of itch is more related to chronic itch, where antihistamines do not have any anti-itch effect.

New TriCalm Hydrogel is steroid-free and is now available at Walgreens, CVS and other retailers.

TriCalm is a product of Cosmederm Bioscience, a specialty pharmaceutical company focused on dermatology and pain management. Drawing on years of laboratory research and published clinical work, Cosmederm develops products that target a wide variety of skin diseases and inflammatory conditions. With its portfolio of patented analgesic and anti-inflammatory compounds, Cosmederm has developed uniquely effective topical products ranging from cosmeceuticals and OTC drugs to a pipeline of prescription drug candidates. Cosmederm is the sole owner of COSMEDERM-7, a patented compound made from strontium that has been developed for dermatological applications. Cosmederm's product lines include TriCalm™, REFINITY™ Skin Solutions, and COSMEDERM SKIN SCIENCE™.

SOURCE Cosmederm Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Baptist Medical Center Jacksonville ... is the only hospital in the region providing what is known as the ... pacing patients were revealed recently at a medical conference and published in The ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot wounds ... Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health care ... to diseases of the diabetic foot. The American Board of Multiple Specialties ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s latest white paper, “ ... a main “pain point” for merging or aligning healthcare provider organizations—when mergers and ... signed. This quick-read guidance suggests that failing to recognize the power of ...
Breaking Medicine News(10 mins):